Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and dok-7 myasthenia

Muscle and Nerve

Volumn 44, Issue 5, 2011, Pages 789-794

  Liewluck, Teerin ^a   Selcen, Duygu ^a   Engel, Andrew G ^a  

^a Mayo Clinic   (United States)

Author keywords

Albuterol; Congenital myasthenic syndrome; Dok 7 myasthenia; Endplate ache deficiency

Indexed keywords

3,4 DIAMINOPYRIDINE; AGRIN; CHOLINESTERASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; LAMININ; MUSCLE SPECIFIC KINASE; PLECTIN; PREDNISONE; PROTEIN KINASE; SALBUTAMOL; UNCLASSIFIED DRUG;

ACETYLCHOLINESTERASE DEFICIENCY; ARTICLE; BEDTIME DOSAGE; CHILD; CLINICAL ARTICLE; CONGENITAL MYASTHENIC SYNDROME; DAILY LIFE ACTIVITY; DISABILITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; ENZYME DEFICIENCY; EXERCISE; FEMALE; HEART ATRIUM FLUTTER; HUMAN; HYPERTENSION; INFANT; INSOMNIA; MALE; MORNING DOSAGE; MUSCLE CRAMP; MUSCLE STRENGTH; NERVE ENDING; NERVOUSNESS; OPEN STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT; SKELETAL MUSCLE; TISSUE SPECIFICITY; TREATMENT RESPONSE; TREMOR;

ACETYLCHOLINESTERASE; ADOLESCENT; ADULT; ALBUTEROL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ENDPLATE; MUSCLE PROTEINS; MYASTHENIC SYNDROMES, CONGENITAL; QUESTIONNAIRES; YOUNG ADULT;

EID: 80054848752     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22176     Document Type: Article

References (31)

1. Engel AG, Shen XM, Selcen D, Sine SM. What have we learned from the congenital myasthenic syndromes? J Mol Neurosci 2010;40:143-153.
2. Engel AG. The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007;4:252-257.
3. Maselli RA, Ng JJ, Anderson JA, Cagney O, Arredondo J, Williams C, et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 2009;46:203-208.
4. Chevessier F, Faraut B, Ravel-Chapuis A, Richard P, Gaudon K, Bauche S, et al. MuSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 2004;13:3229-3240.
5. Mihaylova V, Salih MA, Mukhtar MM, Abuzeid HA, El-Sadig SM, von der Hagen M, et al. Refinement of the clinical phenotype in MuSKrelated congenital myasthenic syndromes. Neurology 2009;73: 1926-1928.
6. Huze C, Bauche S, Richard P, Chevessier F, Goillot E, Gaudon K, et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009;85: 155-167.
7. Banwell BL, Russel J, Fukudome T, Shen XM, Stilling G, Engel AG. Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. J Neuropathol Exp Neurol 1999;58:832-846.
8. Selcen D, Juel VC, Hobson-Webb LD, Smith EC, Stickler DE, Bite AV, et al. Myasthenic syndrome caused by plectinopathy. Neurology 2011;76:327-336.
9. Forrest K, Mellerio JE, Robb S, Dopping-Hepenstal PJ, McGrath JA, Liu L, et al. Congenital muscular dystrophy, myasthenic symptoms and epidermolysis bullosa simplex (EBS) associated with mutations in the PLEC1 gene encoding plectin. Neuromuscul Disord 2010;20: 709-711.
10. Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 11th ed. New York: McGraw-Hill; 2006. p 237-296.
11. Edgeworth H. A report of progress on the use of ephedrine in a case of myasthenia gravis. JAMA 1930;94:1136
12. Bestue-Cardiel M, Saenz /xnamexde Cabezon-Alvarez/x/namex A, Capablo-Liesa JL, Lopez-Pison J, Pena-Segura JL, Martin-Martinez J, et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 2005;65:144-146.
13. Mihaylova V, Muller JS, Vilchez JJ, Salih MA, Kabiraj MM, D'Amico A, et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 2008;131:747-759.
14. Selcen D, Milone M, Shen XM, Harper CM, Stans AA, Wieben ED, et al. Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Ann Neurol 2008;64:71-87.
15. Schara U, Barisic N, Deschauer M, Lindberg C, Straub V, Strigl-Pill N, et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK-7 mutations. Neuromuscul Disord 2009;19:828-832.
16. Lashley D, Palace J, Jayawant S, Robb S, Beeson D. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK-7. Neurology 2010;74:1517-1523.
17. Engel AG, Lambert EH, Gomez MR. A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann Neurol 1977;1:315-330.
18. Hutchinson DO, Walls TJ, Nakano S, Camp S, Taylor P, Harper CM, et al. Congenital endplate acetylcholinesterase deficiency. Brain 1993;116:633-653.
19. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52: 1487-1489.
20. Muller JS, Herczegfalvi A, Vilchez JJ, Colomer J, Bachinski LL, Mihaylova V, et al. Phenotypical spectrum of DOK-7 mutations in congenital myasthenic syndromes. Brain 2007;130:1497-1506.
21. Palmer KN. Muscle cramp and oral salbutamol. BMJ 1978;2:833.
22. Craig TJ, Smits W, Soontornniyomkiu V. Elevation of creatine kinase from skeletal muscle associated with inhaled albuterol. Ann Allergy Asthma Immunol 1996;77:488-490.
23. Hellier JP, Baudrimont M, Dussaule JC, Berenbaum F. Reversible selective beta(2)-adrenoceptor agonist-induced myopathy. Rheumatology (Oxford, UK) 2002;41:111-113.
24. Sieb JP, Engel AG. Ephedrine: effects on neuromuscular transmission. Brain Res 1993;623:167-171.
25. Milone M, Engel AG. Block of the endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine, and albuterol. Brain Res 1996;740:346-352.
26. Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008;88:729-767.
27. Wessler I. Acetylcholine at motor nerves: storage, release, and presynaptic modulation by autoreceptors and adrenoceptors. Int Rev Neurobiol 1992;34:283-384.
28. Besalduch N, Tomas M, Santafe MM, Garcia N, Tomas J, Lanuza MA. Synaptic activity-related classical protein kinase C isoform localization in the adult rat neuromuscular synapse. J Comp Neurol 2010;518:211-228.
29. Westfall TC, Westfall DP. Neurotransmission: the autonomic and somatic motor nervous systems. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 11th ed. New York: McGraw-Hill; 2006. p 137-181.
30. Roder IV, Choi KR, Reischl M, Petersen Y, Diefenbacher ME, Zaccolo M, et al. Myosin Va cooperates with PKA RIalpha to mediate maintenance of the endplate in vivo. Proc Natl Acad Sci USA 2010; 107:2031-2036.
31. Xu R, Salpeter MM. Protein kinase A regulates the degradation rate of Rs acetylcholine receptors. J Cell Physiol 1995;165:30-39.